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CHAPTER I 
lllSTORICAL 
Intrcxluction 
The term "retinoids" is employed to encompass members of the vitamin A group of 
compounds, their derivatives, and their analogues.92 Vitamin A refers to the all-trans-
retinol (1), and some of the relatives 2-5 of vitamin A (1) are illustrated below. 
19 20 
11 13 15 
o ~2 ~4 OH 
18 1 [Retinol, vitamin A] 
~ 
3 [B-Carotene] 
4 [Retinoic acid] 
OH 
~0 
H 
~ ~ ~ ~0 
2 [Retinal] 
OAc 
5 [Retinyl acetate] 
As far back as about 1500 B.C., Egyptian writings have described the benefits of liver 
as a food for the treatment of night blindness. 60 In 1909, a fat soluble extract from egg 
yolk was found to be essential to life.97,98 This substance, initially called "fat soluble 
A",62 was also found in animal fats and fish oils and was subsequently called vitamin A 
(1).26 In 1931, Karrer and co-workers29,54 isolated and purified vitamin A (1) from 
1 
2 
halibut liver oil and determined its structural formula. In the next two decades, retinal 
(2)3,105 and retinoic acid (4)1,75,93,94 were synthesized and shown to be important in the 
visual cycle and in growth, respectively. Since then, various research groups have directed 
efforts at the total synthesis of vitamin A (1), and, among them, the contributions from 
Hoffmann-La Roche (1947)47 and Badische Anilin und Sodafabrik (BASF)78 have been 
particularly noteworthy. Isler and co-workers47 at Hoffmann-La Roche effected the 
chemical synthesis of 1 as illustrated. 
~0 
6 
, CHO 
(1) Mg, EtBr, Ether,~ 
10 
H 
(2) .-... / 
H6~ (9) 
8 
(3) 8 
OH (1) <#f6. Pyr OAc 
11 12 
(1) d, 1-a-Tocopherol 
1 
3 
In the first step, pseudoionone (6) was cyclized to give .B-ionone (7) using sulfuric 
acid.45 The .B-C14 aldehyde 8 was obtained by adding ethyl chloroacetate to .B-ionone (7) 
using the Darzens condensation method. Upon treatment with cis-3-methyl-2-penten-4-yn-
1-ol (9), aldehyde 8 gave diollO. Partial hydrogenation of 10 yielded the diol11 which, 
upon monoacetylation, dehydration, and rearrangement, gave the acetate 5. Vitamin A (1) 
was finally obtained by saponification of 5. Pommer78 of BASF attempted the synthesis 
of vitamin A (1) using the known Wittig reactionllO in the penultimate step as outlined 
below. 
0 1. HC == CNa (13) OH'H 
2. H30+ 
7 14 
lH' + 
PPh3·Cl 
Ph3P·HC1 (16) , 
OH 
17 15 
!.Base~ 
2.0HC OAc (18) 
5 --------..1 
In this route B-ionone (7) was also used as the starting material to which sodium 
acetylide (13) was added followed by hydrolysis to yield 14, which on partial 
hydrogenation gave .B-vinyl ionol (15). The phosphonium salt 17 was obtained upon 
treating alcohol15 with triphenylphosphine hydrochloride (16). Finally, a Wittig reaction 
gave retinyl acetate (5) which was then saponified to yield vitamin A (1). 
4 
Chemistry and Biology ofRetinoids 
Vitamin A (1) and its naturally occurring analogues are 20-carbon diterpenes isolated 
chiefly from fish liver oils, visceral parts of fish, eggs, animal kidney, lungs, eyes, and 
intestinal mucosa. 2 Investigative work on retinoids began with the observation that vitamin 
A (1) regulates the differentiation and proliferation of epithelial tissues.89,109 Wolbacklll 
in 1925 was the first to describe cell differentiation by retinol (1). His study showed that 
changes from normal epithelium to squamous keratinization in mucous membranes arose 
from deficiencies of retinol (1). Since deficiencies of vitamin A (1) produce 
hyperkeratinization, it was hypothesized that analogues of vitamin A (1) might be beneficial 
in the treatment of dermatological disorders like psoriasis, acne and similiar maladies)Ol 
In 1926, Fujimaki36 demonstrated that rats fed on a diet deficient in vitamin A (1) 
developed carcinomas of the stomach. Vitamin A (1) has also been found to inhibit 
tracheobronchial tumors in a study which used Syrian golden hamsters. 82 In this 
investigation, the carcinogen used was benzo[a]pyrene suspended in saline. Normal 
exposure to such a carcinogen generally results in 100% formation of respiratory tract 
tumors. It was found that of the 46 hamsters treated with vitamin A (1) only two 
developed tumors. 82 
A controversy arose when .B-carotene (3), a plant product, was also discovered to be 
effective in curing the symptoms of vitamin A (1) deficiency in rats when the former was 
administered in daily doses of 5 ~g.28 Later, Moore65,66 and Capper14 demonstrated the 
appearance of vitamin A (1) in the liver of vitamin A (1) deficient rats which had been 
given .B-carotene (3). The enzymatic conversion of .B-carotene (3) to retinol (1), and then 
to retinal (2), in the intestinal mucosa and liver of animals has been confmned.40 In 1930, 
Karrer and co-workers established the structure of .B-carotene (3). 52,53 
In 1946, retinoic acid (4), another derivative of vitamin A (1), was synthesized and 
many in-depth studies were completed on the chemistry and biochemistry of acid 4.1•93•94 
5 
It was shown by Bollag6-9 that acid 4 had a prophylactic effect on the generation of 
papillomas (induced originally by 7,12-dimethylbenz[a]-anthrene) by either diminishing or 
delaying the occurrence of these tumors as compared to a control. Additional studies led to 
the hypothesis that retinoids may play a role in the prevention and treatment of tissue 
disorders, including cancer.42,95 Therefore, it seeined logical to conclude that within the 
retinoid family certain chemotherapeutic agents may exist which might reduce the number 
of deaths resulting from epithelium malignancies. 2 
A problem with vitamin A (1) or its esters is that they are stored in the liver, and thus it 
is not possible to raise its concentration significantly in the blood stream. 88,89 In addition, 
it has been shown that upon administration of high concentrations the natural retinoids 
become toxic leading to a condition called as "hypervitaminosis" _18 Thus, the natural 
retinoids have limited clinical utility and this has provided an impetus to search for modified 
retinoids which might possess not only enhanced activity but also low toxicity. 
Mechanism of Retinoid Action 
To date, there are various mechanisms that have been proposed to explain the 
mechanism of retinoid action.33,39,40,43,72,81,89 It was shown by Green and co-workers 
that retinoids suppress the synthesis of a 67-kDa keratin (a fibrous protein) at the level of 
mRNA, synthesis.35 Moreover, Wang and co-workers107 found that trans-retinoic acid 
(4) regulated the transcription of nucleotide sequences in DNA ofF9 cells (a certain type of 
murine cancer cell). In 1935 Wald demonstrated the importance of"retinene", a vitamin A 
derivative in the visual cycle_l04,105 Later, Morton established the identity of retinene as 
vitamin A aldehyde [retinal (2)], which is the product of enzymatic cleavage of B-carotene 
(3) via synthesis from retinol (1)67,68 In other tissues, the fate of retinol (1) is not yet 
clear and is still a subject of investigation.39 
6 
Retinoic acid (4) was shown to be important for growth.l Intracellularly, retinoic acid 
(4) binds to cellular retinoic acid binding protein (cRABP)l6,73,83,85,86 and can be 
translocated within the cell as the RA-cRABP complex. 83 It is believed that cRABP may 
have a major role in mediating some of the biological effects ofretinoic acid (4)_16,58,100 
Most normal cells also appear to possess a 14, 600-dalton, cellular retinol-binding protein 
(cRBP) that binds specifically to retinol (1). This protein, although immunologically 
different from cRABP, has a similar molecular weight and a related amino acid sequence. 27 
Nevertheless, the cRBP and cRABP each appear to have a single specific retinoid binding 
site.15 A recent discovery made by Chambon, Evans and co-workers identified a protein 
receptor that contained a DNA binding domain as well as a ligand binding site.38,77 
Among the possible ligands, it was found that trans-retinoic acid (4) was a ligand to which 
the polypeptide receptor bound not only specifically but also with a high degree of affinity. 
A cloned full length eDNA was isolated and characterized by Evans and co-workers.38 
This eDNA (called as A.hKlR) encodes a 462 amino acid polypeptide whose molecular 
mass is 50,772 and is labelled as hRR (human retinoic acid receptor). Experimentally, they 
discovered a gene sequence whose polypeptide product contained a DNA binding domain 
as well as a region for the specific binding of trans-retinoic acid (4). The retinoids may 
function in a more sophisticated manner then realized at present, but the work of Evans, 
Chambon, and co-workers provides insight as to how retinoid "mimics" might be 
constructed which could possibly be quite effective in controlling the replication of 
malignant cells. 
There is evidence which suggests that the transportation of vitamin A (1) involves two 
plasma proteins, namely RBP (retinol binding protein) and transthyretin.39,90 Vitamin A 
(1) is bound to RBP as a complex and this, in tum, forms another protein-protein complex 
with transthyretin.91 It is these proteins which play an important role in the translocation of 
vitamin A (1) from its storage point to the tissues. Deficiency of retinol (1) blocks RBP 
secretion with the consequence that while the level of plasma RBP falls, the level of the 
7 
liver RBP rises.39 It has been shown that when retinol (1) was injected into vitamin A 
deficient rats there was a rapid secretion of RBP from the liver into the plasma)03 In the 
treatment of actinic and non-actinic keratosis, it was revealed that retinal (3) is effective in 
concentrations between 0.05 and 1.00 weight percent in 95% ethanol or propylene 
glycol)6,112 
The interrelationship of retinol (1), retinal (2) and retinoic acid (4), as well as their 
biological roles has been reviewed by Lotan 58 and is outlined in the diagram below. In a 
reversible process, retinol (1) is oxidized in vivo to retinal (3) which is important in the 
DIFFERENTIATION AND 
MAINTENANCE OF 
EPITHELIAL TISSUE 
RETINOL 
RETINAL VISION 
RETINOIC ACID 
vision process. Although retinoic acid (4) is a major oxidative metabolite of retinol (1), it 
is rapidly excreted, unlike 4 which is stored in the liver. Retinol (1) is necessary for 
growth, differentiation, maintenance of epithelial tissue, and also for reproduction. 
Retinoic acid (4) can substitute for retinol (1) in vitamin A deficient animals in growth 
promotion, in epithelial differentiation and in maintenance. However, 4 can neither 
substitute completely for retinol (1) in maintaining the reproductive function nor replace 
retinal (3) in the visual cycle. 
8 
Arotinoids and Heteroarotinoids 
Incorporation of an aromatic ring into the skeleton of a retinoid system in some cases 
vastly improves the therapeutic ratio relative to retinoic acid (4) by a factor of as much as 
10.93,94 Such compounds are called "arotinoids", and the name has been reserved for 
systems containing an aryl ring within the side chain or fused to the cyclohexyl ring.94 
Some of these retinoids were prepared at Hoffmann-La Roche by Bollag and co-workers& 
during the 1970's. Swiss albino mice were tested and the therapeutic ratio of test retinoids 
was determined from the dose (mglkg) which caused regression of papillomas in the mice 
relative to that dose which produced hypervitaminosis. Many arotinoids have shown a 
high activity in the tracheal organ culture (TOC),20,84 ornithine decarboxylase (0DC),103 
and human promyelocytic leukemia cell line (HL-60)10-13 assays. However, a major 
disadvantage was the high toxicity of arotinoids. Thus, although these arotinoids appeared 
quite promising, alternate compounds had to be found in order to decrease the high 
toxicity. Several research groups have prepared modified retinoids with goals to produce 
both high activity and low toxicity.20,21,79,96,108 Efforts have been expended to change 
the cyclohexy 1 skeleton, leaving the rest of the molecule intact as shown below. 
2 
3 
16 17 
Nonpolar end 
Polyene chain 
20 I 
Polar end 
1 [Retinol, vitamin A] 
It has been found that replacing C(4) with heteroatoms, such as 0, NR, or S, produced 
"heteroarotinoids" with useful properties. These new compounds have been investigated 
separately by the research groups of Berlin79,96,108 and Dawson.20-27,64 Heteroarotinoids 
9 
are a class of retinoids which possess at least one aryl ring and a heteroatom, usually in the 
partially saturated ring as shown. One can see that there is a resemblance in 19 to the basic 
4 
OH 
~0 
19 
structure in trans-retinoic acid ( 4) as illustrated by the broken lines in the drawing. A few 
papers have appeared on the chemistry and structure-activity (SA) relationships24,49-
51,64,79,96,108 of some heteroarotinoids, but the data are relatively sparse to date. 
However, preliminary results from two studies24,37,55 on the toxicity of certain 
heteroarotinoids have indicated the presence of the heteroatom resulted in reduced toxicity 
compared to trans-retinoic acid (4) which has exhibited powerful activity in several assays 
but is highly toxic.24 The heteroarotinoids 20-51 currently in the literature or available in 
our laboratory are illustrated. 
R 
20 X= O,R = C02Me 
21 X = S, R = C02Me 
22 X = 0, R = C02H 
23 X = S, R == C02H 
R 
24 X = 0, R = C02Me 
25 X = S, R = C02Me 
26 X = 0, R = C02Me 
27 X = S, R = C02Me 
29 X = 0, R = C02H 
30 X = S, R = C02H 
33 
31 R = C02Et 
32 R = C02H 
z 
R 
34 Z = C02H 38 Z = CH20H 
35 Z = C02CH3 39 Z = CH2NH2 
36 Z = CN 40 Z = C(O)CH3 
37 Z = CHO 
10 
Ar 
42 Ar = 4-C6H4C02CHg 
R=CH20H 
~ 
HPC02H 
-k I # 
# 0 
47 
49 
11 
z 
44 Z = CN, R = CH3 
12 
52 
A commonly held belief is that the carboxylic acid forms of retinoids are the active 
forms in vivo because of their ability to bind to cRABP, and therefore many tests have been 
reported for retinoids containing the carboxylic acid moiety as shown in Table I. 7 The 
arotinoids prepared by Dawson and co-workers20-25 also showed good activity as 
illustrated in Table II. Among these, the naphthalene derivative 52 showed good activity in 
the ornithine decarboxylase (ODC) assay and also an activity better than retinoic acid in the 
tracheal organ culture (TOC) assay.24 Later, it was found that 52 is extremely 
toxic.24,37,55 The heteroarotinoids 20-23 have been assessed both for their ODC activity 
and their ability to induce differentiation· in HL-60 cells.37 Results of the ODC assay 
correlate well with the ability of the test substance to inhibit tumor formation in mice and 
for the general procedure see the section on Assays of Retinoids. It can be inferred from 
Table IIJ37 that the heteroarotinoids 21 and 23, which contain a sulfur atom, showed very 
high activity as compared to the control 4. The oxygen containing heteroarotinoids 20 and 
22 showed less activity than 4. The increase in acti~ty upon replacing oxygen with sulfur 
has also been noted by Berlin and co-workers.96 
In order to provide a bac~ground for the discussion of our results, it is necessary to 
describe a working hypothesis which was to be tested via several bioassays of the expected 
products. If binding to a transport molecule is important in the biological function of trans-
retinoic acid (4), it is implied that any retinoid mimic must possess certain structural 
features for effective binding. Such parameters have never been probed from the viewpoint 
of a heteroarotinoid mimic. Although it is conceivable that the nonpolar, hydrocarbon ring 
TABLE I 
THE AB~ITY OF AROTINOIDS TO INDUCE DIFFERENTIATION IN THE 
HUMAN PROMELOCYTIC LEUKEMIA CELL LINE (HL-60) AND TO 
INHIBIT COMPLETE SCALE FORMATION IN THE 
Arotinoid 
53 
55 
SKIN OF CHICK EMBRYO FOOT SKINa 
COzH 
COzH 
COzH 
Induction of differentiation 
HL-60 assayb 
ED so 
8 x w-8 
8 x w-9 
e 
7 x w-8 
Complete inhibition 
of scale formation, 
M 
w-7 
aReference 7. bSee Assays ofretinoids. cFor comparison only, not an arotinoid. 
dReference 12. ~ot reported. 
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TABLE II 
ACTIVITY OF SElECTED AROTINOIDS lN TilE TOC 
AND ODC ASSAYSa 
Arotinoid TOC Assay 
COzH 
52 
56 
57 
aReference 13 
ED50, M 
(mg/kg/day) 
3 x w-12 
1 x w-12 
6 x w-10 
hpor comparison only, not an arotinoid 
O:DC 
dose, nmol % inhibition c 
of control 
1.7 88 
17 
1.7 
17 
1.7 
17 
1.7 
80 
56 
91 
89 
69 
33 
c [100 x ODC activity (control)- ODC activity (retinoid)] 
%Inhibition= ------------------
ODC activity (control) 
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TABLE III 
ODC ACTIVITY OF HETEROAROTINOIDS 20-23a 
Test system 
Acetone + TP A 
4 +TPA 
20 + TPA 
Acetone + TP A 
4+TPA 
21 + TPA 
22 + TPA 
23 + TPA 
~eference 37 
~ercent Inhibition = 
R 20 X = 0, R = C02Me 
21 X = S, R = C02Me 
Retinoid 
dose, nmol 
0 
34 
34 
0 
34 
34 
34 
34 
22 X=O,R=C02H 
23 X = S, R = C02H 
ODC 
Activity 
5.3 ± 0.7c 
1.0 ± 0.1 c 
1.5 
Percent 
Inhibition b 
0 (control) 
81 
72 
0 (control) 
87 
94 
72 
91 
ODC activity (control)- ODC activity (retinoid+ TPA) 
ODC activity (control) 
c nmol C02f60 min/mg protein 
d nmol C02f30 min/mg protein 
15 
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system and polar carboxyl group at opposite ends of the molecule in trans-retinoic acid (4) 
are critical for binding, one might envision that the replacement of certain atoms in the 
nonpolar section might be tolerated which in turn would also produce a mimic with greater 
aqueous solubility. Thus it was decided that a somewhat more polar group would be 
inserted into the nonpolar end of some heteroarotinoids. 
The presence of the geminal dimethyl groups in the partially saturated ring system of 
most natural retinoids is well documented.94 The size of two methyl groups might be 
assessed on the basis of van der Waals radii and expected C-C bond lengths. As a 
substitute, a group with nonbonding pairs of electrons might be inserted for the C(CH3)2 
group. The choice of such a substitute group is limited since it would be anticipated that a 
steric factor might arise with a large group or additional interactive forces might prevent or 
alter binding in an unacceptable manner if, for example, hydrogen bonding were involved 
with an 0-H, N-H, or S-H group. If one compares structural characteristics of an oxygen 
atom (with its two sets of nonbonding electron pairs) to the C(CH3)3 group, the former 
will occupy less space [van der Waals radii for 0 (140 pm, 1 pm = IQ-2 A) and CH3 (200 
pm)5]. The smaller radius for oxygen would be expected since the lone pairs of electrons 
are drawn closer to the nucleus.s In an ideal situation, that is, when a tetrahedral carbon is 
surrounded by four identical groups or atoms, the bond angles will be 109° 27'.5 In the 
case of propane (58), the C-C-C bond angle (112.) is larger than the tetrahedral angle 
owing to the "Thorpe-Ingold" effect.5 The latter arises when groups attempt to maximize 
nonbonding contact. This, in tum, causes a compression of the angle between the 
remaining two groups, especially if the groups are C-H. In case of the ether 595, the bond 
angle between the two methyl groups is 111 o which suggests that the angle between the 
orbitals of the two sets of non bonding electron pairs is compressed. Thus orbitals holding 
nonbonding pairs are commonly more compressed than orbitals holding bonding electron 
pairs such as in C-C bonds or in C-H bonds. An interesting point of comparison 
concerning the C-0-C angle is found in 60 from X-ray diffraction data on a crysta1.4 The 
17 
Br 
H 60 
internal angle in question was determined to be 114.0°(4)4 which indicates considerable 
expansion probably to minimize internal strain resulting from both attached or nearby 
groups as well as from angular deformation in the ring. Thus, the two orbitals on the 
oxygen atom in 60 must be compressed and are possibly shielded to some degree by the 
adjacent methylene hydrogens and the peri hydrogen as illustrated above. Since 60 is a 
close model system to compounds in our work, analogous conclusions regarding structural 
characteristics may be reasonable but must be taken with caution since no X-ray data are 
available on our systems. 
Assays of Retinoids 
There are numerous methods developed to test for antitumor activity in a retinoid.94 
Among these, two methods shall be discussed briefly, J;lamely: (1) in vivo methodsl02,103 
[ornithine decarboxylase (ODC) and tracheal organ culture (TQC) assays], and (2) in vitro 
methods12,13[the human promyelocytic leukemia cell line (HL-60) assay]. Regarding the 
in vivo method, Verma and co-workers102,103 have shown that the ability of a test 
substance (in our case, a retinoid) to inhibit the biosynthesis of the enzyme ornithine 
decarboxylase (ODC) can be measured and reflects the extent to which the test substance is 
capable of inhibiting skin tumor production. A potent promoter of cancerous activity is 12-
0-tetradecanoylphorbol-13-acetate (TPA), and the ability of a retinoid to inhibit ODC 
synthesis can be regarded as a measure of its ability to inhibit skin tumor promotion.1°2•103 
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In this method, the backs of mice are shaven 3-4 days prior to treatment with TP A. An 
hour prior to treatment with TPA (8-17 mmol in acetone), mice are pretreated with a test 
retinoid (usually 17 or 34 mmol in acetone). After 4-5 hours, the mice are sacrificed and 
the epidermis is separated, homogenized, and centrifuged. The ODC activity is then 
determined from the soluble extracts by measurement of the release of 14C02 from 14C-
labelled ornithine. The percent inhibition of ODC is determined as follows: 
% Inhibition = [100 x ODC activiftc (control) - ODC activity (retinoid)] 
0 C act1v1ty (control) 
The experiment is run simultaneously with mice treated similarly but with a standard, for 
example all-trans-retinoic acid (4), which shows high activity in this assay.24,94,96,108 
Regarding an in vitro assay, one such method is called the HL-60 assay which is used 
to assess the potential of the test substance to induce differentiation in cells derived from a 
patient with acute promyelocytic leukemia.l2,13 The HL-60 cells do not produce 
superoxide anions upon stimulation by agents like TP A, whereas differentiated HL-60 cells 
do so. The presence of such anions can be detected by their ability to reduce the water 
soluble yellow dye nitroblue tetrazolium (NBT)3 to the water insoluble blue-black 
formazan13 by phagocytizing neutrophils,87 a reaction mediated by superoxide ions, (Oz-) 
obtained from the reduction of oxygen during phagocytosis.17 The percentage of 
differentiated cells (obtained by counting the number of cells containing this dark precipitate 
under a light microscope) is a direct indication of the ability of a test substance (retinoid) to 
induce differentiation and is also one convenient way to determine EDso values.7,13,99 
It should be noted that the positive or negative results from any one assay do not 
eliminate or establish the potential carcinostatic activity of a test retinoid in vivo in 
humans.102 For a nearly complete biological proflle, several tests are necessary.1°3 
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Retinoids in Clinical Use 
There have been numerous studies relating retinoids to epidermal disorders and 
cancer.93,94 However, in the U.S. only two retinoids are currently used for the 
dermatologic conditions and none are in use for the treatment of cancer.109 Accutane®, the 
trade name for 13-cis-retinoic acid, or isoretinoin (61), is the only retinoid approved for 
oral use)09 Acid 61 has been adopted for the systemic treatment of severe cystic and 
conglobate acne where the usual remedies have proven ineffective.l09 In fact, 13-cis-
retinoic acid (61) proved sufficiently promising to reach clinical trials in the treatment of 
cancer of skin and bladder)09 Tretinoin [all-trans-retinoic acid (4)] has been effective in 
treating acne topically109 and was found to be more selective than vitamin A (1) in 
preventing established epithelial tumors from developing in mice)09 Tigason® (62, 
OAc 
4 [Tretinoin] S [Retiny 1 acetate] 
61 [Accutane or Isoretinoin] 62 [Etretinate or Tigason] 
Etretinate), a synthetic retinoid, has attracted considerable attention in Europe for the 
treatment of a large number 'of previously highly resistant skin disorders. 18 Ester 62 has 
been introduced clinically (orally) for treating complicated psoriasis and icthyotic 
conditions.l09 Etretinate (62) acts by normalizing the keratini~ation process and its effect 
I 
is largely suppressive rather than curative. Retinyl acetate (5), given orally, has been 
. I 
shown to abolish carcinogen-induced mammary cancer in mice.'il09 
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Toxicology of Retinoids 
Natural vitamin A (1) is too unselective and highly toxic in the doses required for a 
positive therapeutic response and causes gastrointestinal disorders, fatigue, cracking of 
lips, anaemia, liver dysfunction, visual disturbances, pain in limbs and intracranial 
hypertension.56,101,109 In general, the toxic effects of retinol (1), trans-retinoic acid (4) 
and 13-cis-retinoic acid (61) have been well documented.56,101 The toxic side effects of 
retinol (1), inter alia include chelitis, severe headaches, conjuctival inflammation, nausea, 
vomiting, bulging fontanelles in infants, dryness and scaling, and tenderness of bones.lOl 
Side effects from the topical treatment of all-trans-retinoic acid (4, Tretinoin) include skin 
irritation (redness and scaling) and reversible hypopigmentation. 56 Side effects from the 
oral treatment of 13-cis-retinoic acid (61, Accutane) include abdominal pain, conjunctivitis, 
chelitis, xerosis, and excessive thirst)Ol Tigason (62, Etretinate) has side effects which 
include fissured lips, dryness of mouth and nasal mucosa, and alopecia. Two additional 
problems are: (1) increasing reports of abnormalities in liver function in patients who 
received this drug and (2) marked teratogenic properties due to long half-life of the drug 
after chronic therapy. 56 
CHAPTER II 
RESULTS AND DISCUSSION 
Over the past few years, the research groups of Berlin 79,96,108 and Dawson20-25 have 
synthesized several heteroarotinoids with a stilbene (1,2-diarylethene) skeleton which show 
good activity in selected assays. As discussed earlier (see the section on Chemistry and 
Biology of Retinoids), the impetus for the search of new heteroarotinoids arose from the 
desire to reduce the inherent toxicity associated with most retinoids. The X-ray 
crystallography30 has shown that certain stilbene arotinoids resemble trans-retinoic acid (4) 
structurally and also bind well with cellular retinoic acid binding proteins (cRABP).64 The 
commercial availability of 1,4-benzodioxan-6-yl methyl ketone (63) allowed an extension 
of our original work to yield several relatives which could be potential metabolites of the 
basic systems namely, acid 4 and ester 5. 
4 [Retinoic acid] 
OH 
~0 
21 
OAc 
5 [Retinyl acetate] 
22 
Several assays24,57,96,108 have revealed that the arotinoids and heteroarotinoids are 
biologically quite active. Deluca and co-workers69 have demonstrated that certain active 
metabolites obtained from the metabolism of trans-retinoic acid (4) contained polar groups. 
Along the same lines, we felt that incorporating a heteroatom into the cyclohexyl skeleton 
and attaching a polar group in the side chain would not only increase the polarity of the 
molecule but also enhance its ability for hydrogen bonding. The objectives of our work 
were to obtain heteroarotinoids with high hydrophilicity and, hopefully, low toxicity. 
In our laboratory, we have been able to develop methods which have produced a family 
of heteroarotinoids 64-69 as illustrated in Figure 1. In addition to alcohol 68, we 
reasoned that the incorporation of a glycerol derivative might enhance transport in vivo 
64 R=Me 
65 R=H 
C02 Me 
C02R 10 
66 R=Et 
67 R=H 
69 
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Figure 1. Structures of New Heteroarotinords 64-69 
C02R 17 
23 
and improve formulation of such a material for administration purposes. We have been 
able to obtain ester 69 but only in a low yield to date although we are working to optimize 
the yield. Acid 65 is currently at the National Cancer Institute for screening in a new 
evaluation program with a large variety of assays involved. We have been informed that 
the tests will be made available sometime in 1990. 
Syntheses of New Heteroarotinoids 
The six new heteroarotinoids 64-69 can be categorized into two groups, namely (1) 
64, 65, 68 and 69 which have incorporated an aryl moiety that confers a locked cisoid 
conformation, and (2) 66 and 67 which possess a triene side: chain similar to the natural 
retinoids. The fixed trans geometry in the first group of compounds 64, 65 and 69 is 
believed to be responsible for biological activity in siimilar systems.16 Certain 
heteroarotinoids containing a triene side chain have also shown good activity. In one HL-
60 assay,96 heteroarotinoids with the octatrienoic carboxyl side chain have shown better 
activity than the stilbene like heteroarotinoids. 
Initiation of the synthesis of the heteroarotinoid 64 began with the reduction of 
commercial ketone 63 to the alcohol 70 using LiAIH.t. In early attempts to make 70, 
excess LiA1H4 was destroyed by treatment with ethy 1 acetate. However, even after drying 
70 overnight in the Abderhalden at room temperaure, the presence of ethyl acetate was 
visible in the lH NMR spectrum. Therefore, we elected to quench the excess Li.Al.I4 very 
cautiously (dropwise) by adding ordinary tap water to a flask previously cooled with ice 
and water. It was observed that employing such a method ptoduced a clean 1 H spectrum 
of 70. Alcohol 70 was obtained in a yield of more than 98%. It was converted to the 
phosphonium salt 71 by treatment with triphenylphosphine hydrobromide (Ph3P·HBr) in 
methanol as shown in Figure 2. 
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THF 
63 70 
Ph#HBr 
MeOH 
1. n- Buli/hexanes, -78"C 
2. p-OHC-C~-C~Me 
64 (72) 71 
2. Cone. HCI 
65 
Figure 2. Synthesis of 64 and 65 
Isolation of salt 71 posed problems in that a foam obtained upon evaporation of the 
solvent had to be crushed with a spatula, and this proved difficult on many occasions. The 
problem was circumvented by evaporating the solvent at 75°C, over a half hour period 
during which time formation of the foam was maximized. The phosphonium salt obtained 
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in this manner could be used directly without any further purification. Ester 64 was 
generated by forming the Wittig reagent from 71 with a slight excess of n-BuLi and then 
adding an equimolar amount of methyl 4-formylbenzoate (72) at -78°C. The temperature 
was allowed to rise to room temperature over 48 h. Ester (E')-64, was isolated as white 
flakes (mp 91.5-92.5°C) in a yield of 25%. Saponification of (E)-64, using NaOH in 
absolute alcohol:tap water (1:3), yielded acid (E)-65 which had a high melting point (mp 
171-172° C) and appeared as shiny white crystals. 
Syntheses of triene heteroarotinoids 66 and 67 began by treating starting ketone 63 
with viny !magnesium bromide to yield the alcohol 73. The reaction was initiated with a 
tiny amount of methyl iodide, and 73 was obtained in a quantitative yield. Alcohol 73 was 
converted to phosphonium salt 74 using Ph3P·HBr in methanol. Salt 74 was utilized 
without purification to form a Wittig reaction using n-BuLi in hexanes. Treatment of the 
Wittig reagent with ethyl-3-methyl-4-oxocrotonate (75) gave ester 66 (28% yield) as fine 
yellow crystals (mp 86-87°C). Saponification of 66, using KOH in absolute alcohol:tap 
water (2:1), gave the carboxylic acid 67 as yellow crystals (35%)with a melting point of 
181-182°C. The scheme for the preparation of the triene heteroarotinoids 66 and 67 is 
outlined in Figure 3. 
Oxidation of allylic carbons to give allylic alcohols has been well documented.l9 To 
prepare the heteroarotinoid 68, ester 64 was treated with Se02 in 95% ethanol at reflux 
over 24 h. During the course of the reaction, elemental selenium precipitated and was 
filtered out during workup. A yellow oil was obtained, which upon being subjected to 
separation by chromatography using the Chromatotron [silica gel (7:3, hexanes:EtoAc)], 
63 
66 
1. KOHl H20/ EtOH 
2.CH3C02H 
67 
""Br,Mg 
THF 
C02Et 
1. n-BuLilhexanes 
OEt 2.oylAo 
H (75) 
Figure 3. Synthesis of 66 and 67 
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73 
74 
gave the allyl alcohol 68 (20%). A scheme for the method is shown in Figure 4. The 
mechanism believed to be operating in the formation of allylic alcohols using Se02 has been 
reported.11 o 
The glycerol derivative 6 9 was prepared from the acid 6 5 using 
dicyclohexylcarbodiimide (DCC),70 4-dimethylaminopyridine (DMAP), and 2,2-dimethyl-
1,3-dioxolane-4-methanol (76, Solketal) as illustrated in Figure 5. 
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64 95% EtOH, ~x 
Figure 4. Preparation of Heteroarotinoid 68 
65 
DCC, DMAP, CH2Cl2 
H01 0>( (76) 
0 
69 
Figure 5. Preparation of Heteroaroti.noid 69 
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A massive excess of the reagents compared to acid 65 was required since stoichiometric 
amounts resulted only in the recovery of the starting material. The yield of 69 is low and 
we are currently trying alternate conditions to optimize the same. 
Spectral Data for Heteroarotinoids 64-69 
In general, the C=O group in the IR spectra for 64-69 were observed in the range of 
1690 to 1720 cm-1 depending upon conjugation. In the case of acids 65 and 67, a broad 
peak from 2400 to 3400 cm-1 was diagnostic for the carboxyl group. In the proton NMR 
spectrum, the aromatic protons appeared in the range of a 6.8-7.8. The protons H(2) and 
H(3) were visible as one sharp singlet around a 4.27 for 64-69 while C(2) and C(3) 
appeared at 64 ppm in the 13C NMR. The vinyl proton H(11) in 64,65 and 69 was 
consistently visible as a broad singlet around a 6.8. In the case of alcohol 73, the J value 
for the cis coupling between H(11) and H(12a) was found to be 10.6 Hz while that for the 
ttrans coupling between H( 11) and H(12b) was 17.2 Hz. These values agree well with the 
observed normal cis and trans J values.75 A comparison of the UV spectra of the 
diaromatic compounds 64 and 65 versus the triene compounds 66 and 67 reveals that the 
"-max in the former is around 312 nm (trans-stilbene has a A.max of 295 nm89) whereas that 
of the latter is around 347 nm. This is expected due to increased conjugation in the triene 
compounds. 75 
For testing the activity of our compounds, ester 64 and acid 65 were sent to the 
National Cancer Institute (NCI) more than 1.5 years ago. The NCI personnel have 
indicated that the testing will be done in 1990. We have also sent the above samples to the 
Cancer Center at the University of Wisconsin for testing by Dr. A. K. Verma, and we are 
awaiting the results. We are hopeful that the blockage of oxidative sites and increased 
solubility would result in enhanced biological activity as compared to their hydrocarbon 
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counterparts. Moreover, Dr. Verma will determine if the compounds complex with RABP. 
He would also screen compounds 64 and 65 in certain tumor lines which he has in house. 
Conclusions 
In conclusion, the objectives of the work have been met to some degree with the 
development of the syntheses of the target 1,4-benxodioxans. Both systems have been 
obtained, namely that with a phenyl ring as part of the side group and that with a polyene 
chain as the attached side group. In addition, w:e have beeri able to regiospecifically oxidize 
the methyl group on the double bond to a hydroxymethyl function. This compound is a 
potential metabolite of the parent ester 64 and acid 65. We have also prepared, although in 
low yield, a glycerol derivative of the acid 65. The glycerol ester 69 is definitely more 
hydrophilic than either ester 64 or acid 65, and thus the former may be more easily 
formulated for improved biological assay. These novel systems have an oxygen atom 
(with lone pairs) at the 4-position rather than the geminal dimethyl group normally 
associated with retinoids related to trans-retinoic acid (4). The presence of the two orbitals 
containing two pairs of electrons will offer an opportunity to probe the capability of the 
RABP to bind such a system for the generation of a complex that is transported to the cells. 
Unfortunately, no biological data has arrived as yet from NCI or Dr. Verma to allow us to 
assess our reasoning for improved design of other heteroarotinoids. Future research in the 
area should take such biological data into account before arriving at a strategy for 
constructing new members of this family of heterocycles. 
Suggestions for Future Work 
The glycerol derivative 69 was synthesized as a prodrug ,on the assumption that 
cleavage of the ketal would likely occur in vivo. However, to date, we have obtained 69 
only in low yields. One can attempt to increase the yield of 69 by employing alternate 
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approaches such as by using a Ph3P/CCl4 system, so or by employing the acid chloride 
method in the presence of a powerful amine. Once a suitable esterification method has been 
found, one can envision an array of such glycerol derivatives of the known 
heteroarotinoids, if activity is at a useful level in appropriate assays. 
Our present work has focused on the synthesis of 1,4 benzodioxan derivatives, which 
contain incorporated within them oxygen atoms at the 1- and 4-positions. There is 
evidence which suggests that toxicity reduction is associated with compounds containing 
sulfur as the heteroatom.24 Therefore, it would be interesting to synthesize and determine 
the biological activity of similar compounds which contain sulfur as the heteroatom(s) 
instead of the oxygen(s). 
CHAPTER Ill 
EXPERIMENTAL 
All reactions were carried out in an Nz atmosphere using a magnetic stirrer unless 
otherwise stated. Solvents were concentrated using a rotary evaporator. NMR data was 
obtained using a Varian XL-300 NMR spectrometer. The NMR spectra were recorded at 
300 MHz and 75.43 MHz for lH and 13C, respectively. NMR data were recorded in 8 or 
ppm values downfield from TMS using DCCl3. IR spectra were taken on a Perkin-Elmer 
681 IR spectrophotometer. All IR spectra were recorded as films or KBr pellets (for 
solids). UV spectra were taken on the Varian UV Visible Spectrophotometer Model DMS 
200 equipped with an Epson LX-800 printer. Melting Points were determined using a 
Thomas Hoover melting point apparatus and are uncorrected. Mass spectra were taken on 
a VG Analytical Instrument Model ZAB-2SE. 
1-(2.3-Dihydro-1.4-benzodioxan-6-yl)-ethanol (70) 
A 300-mL, three-necked, round-bottomed flask equipped with a magnetic stirrer, 
addition funnel and Nz inlet (positive pressure from an oil bubbler) was flushed with Nz 
for 5 min. Into this flask was placed LiA~ (1.264 g, 33.3 mmol) and dry THF (10 mL). 
A little "fizzing" was observed, and the resulting suspension was stirred under Nz (2 min). 
A solution of the ketone (63, 2.0 g, 11.24 mmol) dissolved in dry TIIF (20 mL) was 
added dropwise via the addition funnel over a period of 10 min. This mixture was boiled 
for 24 h during which time dry ether (2 x 10 mL) was added after 8 hand after 16 h to 
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maintain the volume. After the flask had attained room temperature (about 1 h), it was 
cooled with ice (30 min). Very cautious addition of 5 mL of tap water followed from an 
addition funnel over 20 min to destroy excess LiAII-l4. A white precipitate formed. While 
still cool, the solution was treated with 5% HCl (80 mL) over 10 min with stirring. The 
precipitate fragmented and two layers formed with the aqueous layer containing a 
suspension. After being stirred for 5 min, the contents of the flask were transferred to a 
separatory funnel, and the aqueous layer was extracted (ether, 5 x 15 mL). The combined 
ether extracts were washed with 5% Na2C03 (4 x 25 mL) and finally with saturated NaCl 
(4 x 25 mL). The ether extracts were dried (Na2S04, overnight) and evaporated (rotovap) 
to yield a colorless oil. Removal of traces of solvent (Abderhalden, RT, 0.025 mm, 2 h) 
gave the alcohol 70 as a colorless oil (2.009 g, 98.68%). The material was used without 
further purification: IR (neat) 3700-3100 (0-H) cm-1. lH NMR (DCCl3) () 1.45 [d, 3 H, 
' 
H(10)], 4.25 [s, 4 H, H(2,3)], 4.79 [q, 1 H, H(9)], 6.87 [m, 3 H, Ar-H(5,7,8)]; 13C 
NMR (DCCl3) ppm 24.96 [C(lO)], 64.35 [C(2,3)], 69.91 [C(9)], 117.19 [C(8)], 118.46 
[C(7)], 139.29 [C(6)], 142.82. [C(8a)], 149.39 [C(4a)]. Anal. calcd. for C10H1203: C, 
66.65; H, 6.71. Found: C, 66.84; H, 6.66. 
[1-(2.3-Dihydro 1.4-benzodioxan-6-yl)ethylltriphenyl-
phosphonium Bromide (71) 
In a single-necked, 300-mL, round-bottomed flask equipped with a magnetic stirrer and 
N2 inlet (positive pressure from an oil bubbler) was placed Ph3P·HBr (5.33 g, 15.54 
mmol) in dry CH30H (25 mL). To this suspension, was added, dropwise, via an addition 
funnel, a solution of the alcohol (70, 2.813 g, 15.54 mmol) in dry CH30H (20 mL) over 
a peroid of 10 min. Additional dry CH30H (60 mL) was added to form a homogenous 
solution, and the resulting clear colorless solution was stirred at room temperature under 
N2 (24 h). Upon rotary evaporation, a colorless foam (which solidified) was obtained. 
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The foam was partially crushed with a spatula, and dry ether (30 mL) was added. The 
suspension was stirred at room temperature under N2 (3 h), flltered (aspirator suction), and 
washed (dry ether, 25 mL). Removal of traces of solvent (Abderhalden, RT, 0.025 mm, 
10 h) gave 71 as an off-white powder (7.72 g, 98.30%). The material was used without 
further purification: mp 153-158°C(dec); IR (KBr) 1110 (C-0) cm-1. lH N1vtR (DCCh) 
a 1.74 [dd, 3 H, H(lO)], 4.24 [s, 4 H, H(2,3)], 6.25 [m, 1 H, H(9)], 6.41-6.78 [m, 3 H, 
Ar-H(5,7,8)], 7.46-7.85 [m, 15 H, P(C6Hs)3]. 
Methyl (E)-4-[2-(2.3-Dihydro-1.4-benzodioxan-6-yl)-
1-propenyllbenzoate (64) 
A three-necked, 300-mL, round-bottomed flask equipped with a magnetic stirrer, 
addition funnel, rubber septum, and N2 inlet (positive pressure from an oil bubbler) was 
flushed with N2 for 5 min. In this flask was placed 71 (4.83 g, 9.57 mmol) in dry ether 
(10 mL). To the stirred suspension was added dropwise n-BuLi (2 mL, 0.906 M, 1.81 
mmol) in hexanes over 2 min at room temperature. The appearance of the solution changed 
from colorless to light brown to dark brown at the end of the addition period. The solution 
of the anion was stirred at room temperature (30 min). This Wittig reagent was then cooled 
in a dry ice-acetone bath to -78oC for 1 min, and a solution of methyl4-formylbenzoate 
(72, 1.57 g, 9.57 mmol) in dry ether (10 mL) was added via the addition funnel over 3 
min. After being stirred for an additional 5 min in the cold bath, the mixture was allowed 
to stir at room temperature for 48 h. The color changed from brown to yellow when 
temperature of the mixture reached room temperature and persisted throughout the period. 
The contents of the flask were filtered (aspirator suction) and washed (dry ether, 100 mL). 
Evaporation (rotovap) of the filtrate and removal of traces of solvent (Abderhalden, RT, 
0.025 mm, 30 min) yielded a yellow oil which solidified at room temperature. 
Recrystallization (minimum absolute EtOH) and seeding with a pure crystal gave ester 64 
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(0.747 g, 25.19%): mp 91.5-92.5°C; IR (KBr) 1710 (C=O) cm-1; lH NMR (DCCl3) a 
2.24 [d, J = 1.4 Hz, 3 H, H(10)], 3.92 [s, 3 H, H(l)], 4.27 [s, 4 H, H(2,3)], 6.78 [br s, 
1 H, H(11)], 6.85-8.04 [Ar-H]; 13C NMR (DCCh) ppm 17.6 [C(lO)], 52.1 [C(19)], 64.4 
[C(2,3)], 114.9 [C(5,8)], 117.1 [C(l1)], 119.2 [C(7)], 125.6 [C(13,17)], 127.8 
[C(14,16)], 129.0 [C(15)] 129.4 [C(6)], 137.0 [C(9)], 138.7 [C(12)], 143.2 [C(4a,8a)], 
166.9 [C(18),(C=0)]; mass spectral data for C19H1s04: m/e (M+) 310.1205; Found: 
310.1206. Anal. calcd. for C19H1s04: C, 73.53; H, 5.84. Found: C, 73.75; H, 5.82. 
(E)-4-[2-(2.3-Dihydro-1.4-benzodioxan-6-yl)-
1-propenyllbenzoic Acid (65) 
' 
In a single-necked, 25-mL, round-bottomed flask equipped with a magnetic stirrer, 
spiral condenser, and N2 inlet (positive pressure from an oil bubbler) was placed the ester 
(64, 0.2 g, 0.644 mmol). To this solid was added NaOH pellets (0.129 g, 3.23 mmol), 
absolute alcohol (3 mL), and tap water (9 mL). The suspension became clear on warming 
and was boiled for 5 h. After cooling to room temperature (about 30 min), concentrated 
HCl (12 N) was added dropwise with stirring until the solution became acidic to litmus. 
The white precipitate formed was filtered, and the filtrate was checked for any further 
precipitation (cone. HCl was added until precipitation ceased). The precipitate was washed 
with tap water (30 mL) and air dried for 30 min. Recrystallization (95% EtOH) and drying 
over toluene (Abderhalden, RT, 0.025 mm, 10 h) yielded 65 as shiny, white, fluffy 
crystals (0.148 g, 77.6%): mp 171-172°C; IR (KBr) 3400-2400 (C02H) cm-1; 1H NMR 
(DCC13) a 2.26 [d, J = 1.35 Hz, 3 H, H(lO)], 4.29 [s, 2 H, H(2,3)], 6.80 [br s, 1 H, 
H(ll)], 6.89-8.12 [(Ar-H)]; 13C NMR (DCC13) ppm 17.6 [C(10)], 52.1 [C(19)], 64.4 
[C(2,3)], 114.9 [C(5,8)], 117.1 [C(l1)], 119.2 [C(7)], 125.6 [C(13,17)], 127.8 
[C(14,16)], 129.1 [C(15)], 130.1 [C(6)], 170.9 [C(18)]; mass spectral data for C1sH1604: 
35 
rn/e (M+) 296.1048; Found: 296.1048. Anal. calcd. for C1sH1604: C, 72.96; H, 5.44. 
Found: C, 73.07; H, 5.34. 
2-(2.3-Dihyciro-1.4-benzodioxan-6-yl)-3-buten-2-ol (73) 
A 300-mL, three-necked, round-bottomed flask equippped with a magnetic stir bar, dry-
ice condenser, and N2 inlet (positive pre~sure from an oil bubbler) was flushed with N2 for 
5 min. In the flask was placed Mg turnings (1.52 g, 62.53 mmol) and dry THF (10 mL). 
Vinyl bromide (10 g, 93.45 mmol), collected separately in a 50 mL, single-necked, round-
bottomed flask without solvent and at 0 o C, was added drop wise over 5 min to the original 
flask via an addition funnel. To initiate the reaction, CH3I (0.5 mL) was added and the 
solution began to bubble immediately. After 5 min, an additional quantity of vinyl bromide 
(10 g, 93.45 mmol) in 25 mL of dry THF was added dropwise over 15 min. Stirring the 
mixture for 30 min at room temperature ensured that nearly all of the Mg had dissolved 
while the color of the solution changed from colorless to light brown. Then the ketone 
(63, 4.0 g, 22.45 mmol), dissolved in dry THF (25 mL), was added dropwise through the 
addition funnel over 15 min. The dry-ice condenser was replaced by a spiral water 
condenser, and the solution was boiled for 2 h. After being stirred at room temperaure for 
10 h, the mixture was cooled in a water bath, and a solution of saturated NH4Cl (20 mL) 
was added dropwise initially (about 5 min) and later in 1-mL portions over 10 min. Two 
layers formed and the contents of the flask were transferred to a separatory funnel. 
Extraction of the aqueous layer with ether (4 x 50 mL) followed. The combined ether 
extracts were washed with saturated NaCl (2 x 500 mL) and dried (NazS04, 2 h). 
Evaporation (rotovap) and removal of traces of the solvent (Abderhalden, RT, 0.025 mm, 
1 h) gave crude 73 as a yellow oil ( 4. 78 g, 103% ). This oil was used without further 
purification. IR (neat) 3700-3100 (0-H) cm-1; lH NMR (DCCh) () 1.60 [s, 3 H, H(10)], 
4.23 [s, 4 H, H(2,3)], 5.11 [dd, leis = 10.6 Hz, 1gem = ~.08 Hz, 1 H, H(12b)], 5.27 
I 
I 
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[dd, Itrans == 17.2 Hz, Igem = 1.08 Hz, Igem = 1.08 Hz, 1 H, H(12a)], 6.12 [dd, Itrans == 
17.3 Hz, Jcis = 10.52 Hz, H(ll)], 6.8-6.99 [m, Ar-H, 3 H, H(5,7,8)]; 13C NMR 
(DCCl3) ppm 29.15 [C(10)], 64.33 [C(2,3)], 74.25 [C(9)], 112.03 [C(5)], 114.41 
[C(12)], 116.86 [C(8)], 118.26 [C(7)], 139.96 [C(11)], 142.41 [C(6)], 143.02 [C(8a)], 
144.78 [C(4a)]; mass spectral data for C12H1403: m/e (M+) 206.0942. Found: 
206.0938. 
[3-(2.3-Dihydro-1.4-benzodioxan-6-yl)-2-
buten-1-yl]triphenylphosphonium Bromide (74) 
In a 100-mL, two-necked, round-bottomed flask equipped with an addition funnel, 
magnetic stir bar, and an N2 inlet (positive pressure from an oil bubbler) was placed 
Ph3P·HBr (2.615 g, 4.92 mmol) in dry methanol (20 mL). To this stirred suspension was 
added dropwise, via the addition funnel, a solution of the alcohol (73, 1.015 g, 4.92 
mmol) in dry CH30H (30 mL) over 10 min at room temperature. The suspension became 
a solution and immediately acquired a peach coloration. It was stirred at room temperature 
under N2 for 10 h, concentrated to about 5 mL (rotovap), and transferred to a 600 mL 
beaker. Dry ether (200 mL) was added slowly with hand stirring using a glass rod to 
ensure complete precipitation. Filtration (aspirator suction) and washing with dry ether (20 
mL) gave a white powder which dissolved in dry CH30H (]5 mL). Ether (100 mL) was 
added with constant hand stirring. The beaker was covered with parafilm and stored in the 
freezer overnight. Filtration (aspirator suction) and drying (Abderhalden, RT, 0.025 mm, 
10 h) gave 74 as fine white crystals (2.22 g, 84.92%). The salt was used without further 
purification; mp 234-235°C. IR (KBr) 1110 ( C-0) cm-1; lH NMR (DCCh) a 1.58 [d, 3 
H, H(lO)], 4.22 [s, 4 H, H(2,3)], 4.84 [ dd, JHP = 15.1 Hz; JHH = 8.1 Hz, H(12)], 5.57 
[m, 1 H, H(11)], 6.68 [m, 3 H, H(5,7,8)], 7.65-7.93 [m, 15 H, P(C6Hs)3]; 13C NMR 
ppm (tentative assignments)37 16.82 [C(lO)], 25.3 [C(l2)], 64.3 [C(2,3)], 109.8 [C(l1)], 
37 
118.1 [d, 1Jcp = 85.2 Hz, orthogonal-C's of (C6Hsh], 130.2 [meta-C's of P(C6H5)3] 
134.9 [ortho-C's of P(C6Hsh], 135.5 fpara-C's of P(C6Hsh], 145.6 [C(9)]. Anal. 
calcd. for C3oH2s02PBr·H20: C, 65.58; H, 5.50. Found: C, 65.68; H, 5.45. 
Ethyl (2E.4E.6EJ-7-(2.3-Dihydro-1.4-benzodioxan-
6-yl)-3-methyl-2.4.6-octatrienoate ( 66) 
A three-necked, 100-mL, round-bottomed flask equipped with power stirrer, addition 
funnel, rubber septum, and an Nz inlet (positive pressure from an oil bubbler) was flushed 
with N2 for 5 min. In this system was placed the phosphonium salt (74, 4 g, 7.53 mmol) 
in dry ether (40 mL). To the stirred suspension was added d.ropwise via the septum, n-
BuLi in hexanes (14 mL, 0.906 M, 21.7 mmol) over 5 min. The resulting dark red 
solution was stirred at room temperature for 30 min, and then a solution of ethyl3-methyl-
4-oxocrotonate (75, 1.3 mL, 9.15 mmol) in dry ether (10 mL) was added via the addition 
funnel. The color of the mixture became dark yellow, and it was allowed to stir at room 
temperature for 10 h. Hexanes (100 mL) were added and filtration (suction) followed by 
evaporation, gave a yellow oil. Crystals began forming in the oil at room temperature and 
the mixture was allowed to stand overnight. Recrystallization of the resulting solid mass of 
crystals (minimum absolute EtOH) gave 66 as fine yellow crystals (0.683 g, 28.85%): mp 
86-87° C; IR (KBr) 1699 (C=O) cm-1; lH NMR (DCCI}) a 1.3 [t, J = 7.1 Hz, 3 H, 
H(19)], 2.20 [s, 3 H, H(10)], 2.37 [d, J = 0.98 Hz, 3 H, H(19)], 4.17 [q, J = 7.1 Hz, 2 
H, H(18)], 4.27 [s, 4 H, H(2,3)], 5.78 [br s, 1 H, H(16)] , 6.33 [d, J = 15.1 Hz, 1 H, 
H(13)], 6.51 [d, J = 11.2 Hz, H(ll)], 6.87-7.04 [m, 3 H, H(5,7,8)]; 13C NMR (DCCI}) 
ppm 13.79 [C(19)], 14.34 [C(15)], 16.23 [C(lO)], 59.64 [C(18)], 64.40 [C(2,3)], 114.67 
[C((5)], 117.05 [C(8)], 118.68 [C(7)], 118.92 [C(16)], 125.54 [C(9)], 131.12 C[(12)], 
135.52 [C(13)], 167.15 [C(17),(C=0)]; quarternary C [135.98, 139.16, 143.20, 143.35, 
38 
152.64]; mass spectral data for C19Hzz04: m/e (M+) 314.1510. Found: 314.1518. 
Anal. calcd.for C19Hzz04: C, 72.59; H, 7.053. Found: C, 72.62; H, 7.11. 
(2E.4E.6E )-7-(2.3-Dihydro-1.4-benzodioxan-
6-yl)-3-methyl-2.4.6-octatrienoic Acid (67) 
In a 10-mL, single-necked, round-bottomed flask equipped with a magnetic stir bar, and 
~ 2 inlet was placed the ester (66, 0.150 g, 0.48 mmol). To this system was added 
absolute EtOH (2 mL) and aqueous KOH (1 mL, 35% ). The mixture was boiled for 1 h 
and cooled to room temperaure. To the flask were added tap water (5 rnL), EtOAc (50 
rnL), and AcOH:HzO (1:1, 1 rnL) in that order. Two layers were obtained, and the 
aqueous layer was extracted (EtOAc, 10 rnL). The combined organic layers were dried 
(NazS04, overnight), filtered (aspirator suction), and dried (Abderhalden, RT, 0.025 mrn, 
10 h) to give 67 as yellow crystals (0.49 g, 35.88%): mp 181-182°C. IR (KBr) 3300-
2400 (C02H) cm-1; lH NMR (DCCl3) a 2.21 [s, 3 H, H(lO)], 2.39 [s, 3 H, H(15)], 4.27 
[s, 4 H, H(2, 3)], 5.83 [br s, 1 H, H(16)], 6.38 [d, J = 15 Hz, 1 H, H(13)], 6.53 [d, J = 
11.2 Hz, 1 H, H(11)], 6.83-7.09 [m, 3 H, Ar-H(5,7,8)]; 13C NMR ppm 14.07 [C(15)], 
16.3 [C(10)], 64.4 [C(2,3)], 114.7 [C(5)], 117.1 [C(8)], 119.01 [C(16)], 125.54 [C(9)], 
135.2 [C(13)], 172.08 [C(17),C=0]; mass spectral data for C11H1s04 m/e (M+) 
286.1205; Found: 286.1203. Anal. calcd. for C11H1s04: C, 71.31; H, 6.34. Found: 
C, 71.29; H, 6.31. 
Methyl (E)-4-[2-(2.3-Dihydro-1.4-benzodioxan-
6-yl)-3-hydroxy-2-propen-1-yllbenzoate (68) 
In a 25-rnl, single-necked, round-bottomed flask equipped with a magnetic stir bar, 
spiral water condenser, and N2 inlet from the top of the condenser (positive pressure from 
39 
an oil bubbler) was placed the ester (64, 0.1 g, 0.322 mmol). To the flask was added 
Se02 (0.0357 g, 0.107 mmol) and 15 mL of 95% EtOH. The suspension became 
homogeneous on warming and was boiled for 20 h. After allowing to cool at RT for 2 h, 
the precipitated Se metal was filtered off via a thick pad of glasswool. Ether (10 mL) was 
used to rinse the original flask, and this rinse was also filtered (glasswool). The organic 
solution was concentrated to about 1 mL, filtered (glasswool), washed with ether (5 mL), 
and concentrated a total of three times to remove the precipitated selenium metal. Finally 
the concentrated filtrate was subjected to chromatography using the Chromatotron [silica 
gel (7:3 hexanes:EtOAc)]. The major product was isolated and dried (Abderhalden, 
<0.025 mm, RT overnight) to yield 68 as a thick oil (0.0202 g, 19.22%) (E)-68:(2)-68 
-10:1: IR (neat) 3550-3150 (0-H), 1715 (C=O) cm-1; lH NMR (DCCl3) o 1.71 [s, 0-
H], 3.86 [s, 4 H, H(2,3)], 4.26 [s, 3 H, H(19)], 4.43 [d, 2 H, H(lO)], 6.62 [d, 1 H, 
H(11)], 6.65-7.82 [Ar-H]; 13C NMR ppm 50.89 [C(19)], 64.3 [C(2,3)], 68.2 [C(lO)], 
117.2 [C(11)], 121.8 [C(7)], 124.9 [C(13)], 128.0 [C(14)], 128.6 [C(15)], 141.4 [C 
(12)], 143.3 [C(4a,8a)], 166.9 [C(18),(C=0)]; mass spectral data for C19H1sOs: m/e 
(M+) 326.1164; Found: 326.1161. Anal. calcd. for C19H1s Os·2/3H20: C, 67.45; H, 
5.76. Found: C, 67.83; H, 5.66. 
2,2-Dimethyl-1.3-dioxolyl (E)-4-[2-(2.3-Dihydro-
1.4-benzodioxan-6-yl)-1-propenyl] benzoate (69) 70 
In a 15-mL, two-necked, cone-shaped flask equipped with a magnetic stirrer was placed 
the acid (65, 0.050 g, 0.168 mmol). To the flask was added CH2Ch (3 mL), which had 
been dried overnight (molecular sieves 4A). Then dimethylformamide (DMF, 15 drops) 
was added to dissolve the suspension. To the clear solution was added Solketal (76, 0.1 
mL, 0.84 mmol) and 4-dimethylaminopyridine (DMAP, 0.041 g, 0.336 mmol). The 
solution became pale brown, and it was cooled to 0 ° C with ice and water. 
40 
Dicyclohexylcarbodiimide (DCC, 1 g, 4.85 mmol) was added at OoC and the flask was 
allowed to warm up toRT for 0.5 h. After stirring at RT for an additional4 h, the contents 
of the flask were filtered (aspirator suction), and transferred to a separatory funnel. The 
filtrate was washed sucessively with 0.5 N HCl (2 x 25 mL) and saturated NaHC03 (2 x 
25 rnL). The CHzClz extracts were dried (NazS04, overnight) and evaporated (rotovap) to 
yield a yellow oil with a suspended white precipitate. The mixture was filtered through 
glasswool and washed with 10 mL CHzClz to remove the precipitate. The filtrate was 
concentrated (rotovap) and separated by thin layer chromatography [Chromatotron, 1 mm 
plate (silica gel), 8:2 hexanes:EtOAc] to yield 69 as a yellow oil (0.003 g, 4.2%). IR 
(neat) 1720 (C=O) cm-1; lH NMR (DCCl3) a 1.4 [s, 3 H, H(26)], 1.47 [s, 3 H, H(27)], 
2.24 [d, 3 H, H(10)], 4.29 [s, 4 H, H(2,3)], 6.78 [br s, 1 H, H(ll)], 7-8.05 [Ar-H]; 13C 
NMR ppm 17.6 [C(lO)], 25.4 [C(26)], 26.8 [C(27)], 64.4 [C(2,3)], 73.7 [C(23)], 114.9 
[C(5,8)], 117.1 [C(11)], 119.2 [C(7)], 125.6 [C(l3,17)], 127.3 [C(14,16)], 129.0 
[C(15)], 137.0 [C(9)], 143.2 [C(4a,8a)], 166.2 [C(18),(C=0)]; mass spectral data for 
Cz4H2606: m/e (M+) 410.1729; Found: 410.1732. Anal. calcd. for Cz4H2606: C, 
70.23; H, 6.38. Found: C, 70.41, H, 6.61. 
Other Methods Attempted for Pre.paration of 69 
In one experiment, the ratio of 65:pyridine:SOC12:Solketal (76) was 1:1.2:1.1:1 and the 
reaction mixture was stirred at room temperature under Nz for 12 h. Upon completion of 
the reaction and workup, starting material was obtained. In another experiment, the ratio of 
65:BF3.etherate:Solketal (76) was 1:10:100. The mixture was heated to reflux for 4 h 
and, after workup, only starting material was recovered. 
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